Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-10

Study Completion Date

2018-08-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the Ulthera® System for lifting submental (under the chin) and neck tissue in Chinese patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

NCT07229430

Skin Laxity (Submental and Neck) Facial Skin Laxity Submental Tissue Laxity

RECRUITING NA

Evaluation of the BTL-785F Device for Submental Fat Reduction and Neck Rejuvenation

NCT06274177

Fat Burn

COMPLETED NA

A Multicenter,2-Arm,Randomized,Controlled Study Evaluate the Effectiveness of the UltraShape® Contour I VER 3.1 System for Non-Invasive Reduction in Abdominal Circumference

NCT01462201

Body Sculpting

COMPLETED NA

UltraShape Device for Thigh Fat and Circumference Reduction vs. Control

NCT02488083

Unwanted Thigh Fat

UNKNOWN NA

Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental Fat

NCT05831332

Skin Laxity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild to Moderate Skin Laxity Under the Chin Mild to Moderate Skin Laxity on Neck

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ultherapy®, energy level 3

Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).

Group Type EXPERIMENTAL

Microfocused ultrasound with visualization

Intervention Type DEVICE

All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.

Ultherapy®, energy level 4

Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).

Group Type EXPERIMENTAL

Microfocused ultrasound with visualization

Intervention Type DEVICE

All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.

Ultherapy®, energy level 2

Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).

Group Type EXPERIMENTAL

Microfocused ultrasound with visualization

Intervention Type DEVICE

All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Microfocused ultrasound with visualization

All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ultherapy®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Both parents of full Chinese decent.
2. Mild to moderate skin laxity of the submental (under the chin) and neck tissue as determined by the physician and trained assessors.
3. Adequate menton area to allow for quantitative analysis, as confirmed by photography images.
4. Willingness and ability to comply with protocol requirements, including returning for follow-up visit and abstaining from any other procedures in the areas to be treated through the follow-up period.
5. Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the Screening Visit and be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following conditions is documented on the medical history:

1. Postmenopausal with last menstrual bleeding at least 12 months prior to study; and
2. Without a uterus and/or both ovaries.
6. Willing to take 600mg Ibuprofen as pre-treatment medication, at least 60 minutes but not more than two hours prior to study treatment.
7. Willingness and ability to provide written consent for study-required photography and adherence to photography procedures (i.e., removal of jewelry and makeup).
8. Willingness and ability to provide written informed consent prior to performance of any study-related procedure.

Exclusion Criteria

1. Presence of an active systemic or local skin disease that may affect wound healing.
2. Presence of any hemorrhagic disorder or hemostatic dysfunction, herpes simplex, diabetes, epilepsy, bell's palsy or any physical or psychological condition that is deemed unacceptable by the investigator for participation in this study.
3. Severe solar elastosis.
4. Excessive subcutaneous fat in the area(s) to be treated.
5. Excessive skin laxity on the area(s) to be treated.
6. Significant scarring in the area(s) to be treated that would interfere with assessing results.
7. Open wounds or lesions in the area(s) to be treated.
8. Severe or cystic acne on the area(s) to be treated.
9. Active implants (e.g., pacemakers or defibrillators), or metallic implants in the treatment areas (dental implants not included.)
10. Inability to understand the protocol or to give informed consent.
11. Allergy or sensitivity to pre-treatment medication (ibuprofen).
12. Microdermabrasion, or prescription level glycolic acid treatment to the treatment area(s) within four weeks prior to study participation or during the study.
13. Marked asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area(s) to be treated.
14. BMI greater than or equal to 30.
15. History of chronic drug or alcohol abuse.
16. More than 2-3 doses of any NSAID in any 2-week period prior to and throughout study.
17. History of autoimmune disease.
18. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
19. Subjects who anticipate the need for inpatient surgery or overnight hospitalization during the study.
20. Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.
21. Concurrent enrollment or enrollment in any study involving the use of investigational devices or drugs within the past three months.
22. Current smoker as defined by

1. Having smoked one or more cigarettes per day on a daily basis within the past year; or
2. Smoke cessation within the past 6 months.
23. Current user of any nicotine-containing products, e.g., e-cigarettes, Nicorette gum, nicotine patches, etc.
24. History of the following cosmetic treatments in the area(s) to be treated:

1. Skin tightening procedure within the past year;
2. Injectable filler of any type within the past: i) 9 months for Hyaluronic acid fillers (e.g. Restylane); ii) 24 months for Ca Hydroxyapatite fillers (e.g. Radiesse); iii) 12 months for Long-lasting Hyaluronic acid (Juvéderm Voluma); iv) 24 months for Poly-L-Lactic acid fillers (e.g. Sculptra); v) Ever for permanent fillers (e.g. Silicone, Artecoll)
3. Neurotoxins within the past three months;
4. Ablative resurfacing laser treatment;
5. Nonablative, rejuvenative laser or light treatment within the past six months;
6. Surgical dermabrasion or deep facial peels;
7. Facelifts within the past year; or
8. Any history of contour threads.
25. History (in the prior year) or current use of the following prescription medications:

1. Accutane or other systemic retinoids within the past six months;
2. Topical Retinoids within the past two weeks;
3. Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix);
4. Psychiatric drugs that in the investigators opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.

Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No